Professor Dan Davis and his team at the Manchester Collaborative Centre for Inflammation Research, working in collaboration with global healthcare company GSK, investigated how different types of immune cells communicate with each other - and how they kill cancerous or infected cells. Their research has been published in Nature Communications.
Professor Davis says: "We studied the immune system and then stumbled across something that may explain why some drugs don't work as well as hoped. We found that immune cells secrete molecules to other cells across a very small gap. This happens when immune cells talk to each other and also, when they kill diseased cells. But crucially, some types of drugs aren't able to penetrate the gap between the cells. So they can't easily reach targets within the gap, to work effectively."
The researchers took molecules of different sizes and colours and used microscopic imaging to see which size of molecule could get into the gap between an immune cell and another cell. They found that only the smaller molecules could penetrate the gap.
They even found that when an immune cell attaches to another cell it clears out all but the smallest molecules between them.
Professor Davis explains the significance of their findings: "Our research demonstrates that any drugs targeting immune cells need to be very small. Antibody proteins, for example, are too big and aren't able to get into the gap between the cells - they're even cleared away when cells meet. To make them more effective they must be smaller - something that GSK is working on."
This research leads to new ideas for making drugs that, for example switch off immune activity in auto-immune diseases like diabetes or increasing immune reactivity to cancer. "A lot of important targets for future medicines are in the very small gap between cells. This research demonstrates why in certain cases we may need drug molecules to be smaller to work effectively," said Simon Chell, from GSK's Biopharm R&D team.
PhD student Adam Cartwright played a key role in the research, spending time at GSK as well as in Davis's lab at the University of Manchester.
He says: "Being able to test out our theory with medicines that GSK has designed was fantastic. The idea that something I had found out can be used to develop treatments to help patients is incredibly exciting."
Professor Davis, author of the popular Penguin paperback The Compatibility Gene, concludes: "The practical application of this basic research comes from bouncing around our ideas with scientists working on drug design. The interaction between academia and pharma is hugely beneficial and we hope it will lead to more effective drug treatments."
Notes for editors
Please note the embargo: 10.00am UK time, Wednesday 19 November 2014
The paper 'The immune synapse clears and excludes molecules above a size threshold' is due to be published in Nature Communications. DOI: NCOMMS6479
High resolution images on request.
The Manchester Collaborative Centre for Inflammation Research The MCCIR was established in October 2012 to address current priorities in inflammatory disease in an open innovation, pre-competitive collaboration between academia and the pharmaceutical industry. GlaxoSmithKline, AstraZeneca and The University of Manchester have each invested £5M to promote "blue skies" research over the next 5 years. Our mission is to bring together clinical, industrial, and academic scientists - and innovate at this interface or in this unique interactive environment.
Register to receive news releases: https://www.manchester.ac.uk/discover/news/register-news-releases/
Media enquiries to:
Media Relations Officer
The University of Manchester
Tel: 0161 2758383
Mob: 07887 561318
Jamie Brown | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences